MetaCap

AEON Biopharma (AEON) vs CalciMedica (CALC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AEON Biopharma (AEON) has outperformed CalciMedica (CALC) over the past year, losing 85.2% versus a loss of 92.3%. AEON Biopharma is the larger company by market cap ($10.3 million vs $8.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AEON-85.18%CALC-92.34%
+115%+6%-104%
Nov 21, 20251 yearNov 20, 2026
AEON-99.98%CALC-94.99%
+78%-15%-108%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AEON versus CALC key metrics
MetricAEONCALC
Share price$0.123$1.26
Market cap$10.35M$8.69M
1-day change-7.59%+7.69%
YTD return-88.82%-96.18%
1-year return-85.18%-92.34%
EPS (TTM)$-3.89$-4.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.22M$-29.56M
52-week high$1.45$36.00
52-week low$0.106$1.00
Distance from 52-week high-91.52%-96.50%
Analyst consensusstrong_buynone
Avg. price target upside+1379.67%+3868.25%
Average volume7.44M80.15K
Shares outstanding84.12M6.90M
Employees815
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AEON Biopharma

AEON stock →

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

AEON vs CALC FAQ

Which is bigger, AEON Biopharma or CalciMedica?

AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $8.69M for CalciMedica (CALC).

Which stock has performed better over the past year, AEON or CALC?

AEON returned -85.18% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are AEON Biopharma and CalciMedica in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons